Bellerophon Therapeutics, Inc. 6L7A.F Stock
Bellerophon Therapeutics, Inc. Price Chart
Bellerophon Therapeutics, Inc. 6L7A.F Financial and Trading Overview
| Bellerophon Therapeutics, Inc. stock price | 0.39 EUR |
| Previous Close | 0.63 EUR |
| Open | 0.64 EUR |
| Bid | 0.62 EUR x N/A |
| Ask | 0.68 EUR x N/A |
| Day's Range | 0.64 - 0.64 EUR |
| 52 Week Range | 0.56 - 11.15 EUR |
| Volume | 68.53K EUR |
| Avg. Volume | 82 EUR |
| Market Cap | 6.71M EUR |
| Beta (5Y Monthly) | 0.895847 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25 EUR |
6L7A.F Valuation Measures
| Enterprise Value | -7890915 EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.27203393 |
| PEG Ratio (5 yr expected) | 0 |
| Price/Sales (ttm) | 1.1894985 |
| Price/Book (mrq) | 0.63251233 |
| Enterprise Value/Revenue | -1.399 |
| Enterprise Value/EBITDA | 0.518 |
Trading Information
Bellerophon Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.895847 |
| 52-Week Change | -34.72% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11.15 EUR |
| 52 Week Low | 0.56 EUR |
| 50-Day Moving Average | 7.13 EUR |
| 200-Day Moving Average | 3.07 EUR |
6L7A.F Share Statistics
| Avg. Volume (3 month) | 82 EUR |
| Avg. Daily Volume (10-Days) | 200 EUR |
| Shares Outstanding | 10.45M |
| Float | 7.05M |
| Short Ratio | N/A |
| % Held by Insiders | 4.11% |
| % Held by Institutions | 44.42% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -201.56% |
| Operating Margin (ttm) | -270.70% |
| Gross Margin | 100.00% |
| EBITDA Margin | -269.91% |
Management Effectiveness
| Return on Assets (ttm) | -50.60% |
| Return on Equity (ttm) | -84.92% |
Income Statement
| Revenue (ttm) | 5.64M EUR |
| Revenue Per Share (ttm) | 0.58 EUR |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -15223000 EUR |
| Net Income Avi to Common (ttm) | -11368000 EUR |
| Diluted EPS (ttm) | -1.11 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 15.17M EUR |
| Total Cash Per Share (mrq) | 1.45 EUR |
| Total Debt (mrq) | 8K EUR |
| Total Debt/Equity (mrq) | 0.08 EUR |
| Current Ratio (mrq) | 2.94 |
| Book Value Per Share (mrq) | 1.015 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -9768000 EUR |
| Levered Free Cash Flow (ttm) | -8167500 EUR |
Profile of Bellerophon Therapeutics, Inc.
| Country | Germany |
| State | NJ |
| City | Warren |
| Address | 20 Independence Boulevard |
| ZIP | 07059 |
| Phone | (908) 574-4770 |
| Website | https://bellerophon.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 18 |
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Q&A For Bellerophon Therapeutics, Inc. Stock
What is a current 6L7A.F stock price?
Bellerophon Therapeutics, Inc. 6L7A.F stock price today per share is 0.39 EUR.
How to purchase Bellerophon Therapeutics, Inc. stock?
You can buy 6L7A.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bellerophon Therapeutics, Inc.?
The stock symbol or ticker of Bellerophon Therapeutics, Inc. is 6L7A.F.
Which industry does the Bellerophon Therapeutics, Inc. company belong to?
The Bellerophon Therapeutics, Inc. industry is Biotechnology.
How many shares does Bellerophon Therapeutics, Inc. have in circulation?
The max supply of Bellerophon Therapeutics, Inc. shares is 12.23M.
What is Bellerophon Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Bellerophon Therapeutics, Inc. PE Ratio is 0.00000000 now.
What was Bellerophon Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Bellerophon Therapeutics, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Bellerophon Therapeutics, Inc. company belong to?
The Bellerophon Therapeutics, Inc. sector is Healthcare.